Cagrilintide and Semaglutide 5 mg+5 mg

Cagrilintide and Semaglutide Combo for Sale: Research-Grade Amylin+GLP-1 Dual Agonist Blend

The combination of cagrilintide and semaglutide is the core of Novo Nordisk’s CagriSema clinical program, which produced 22.7% mean weight reduction in the REDEFINE-1 Phase 3 trial. Researchers studying dual-mechanism obesity pharmacology now have a direct tool: a pre-mixed lyophilized blend of long-acting amylin analog (cagrilintide) and GLP-1 receptor agonist (semaglutide) at a 5mg/5mg research ratio. Pure Peptide Factory supplies this domestic, HPLC-verified combination with cold-chain shipping and full batch documentation.

By running cagrilintide and semaglutide together in a single vial, your protocol eliminates the need to source and reconstitute two separate peptides. Moreover, the pre-mixed format ensures that every dose delivers the exact same ratio, removing a significant source of variability in dose-response experiments. This is particularly important when comparing the combo to monotherapy arms, because batch consistency directly affects data reliability.

Why Researchers Choose Pure Peptide Factory for Cagrilintide and Semaglutide

Pre-Mixed Research Ratio You Can Trust

Each vial of the cagrilintide and semaglutide combo contains 5mg of cagrilintide and 5mg of semaglutide as a homogeneous lyophilized powder. Consequently, you avoid the pitfalls of separate reconstitutions where one peptide may dissolve at a different rate or concentration. The 5mg/5mg configuration provides ample material for dose-response studies, head-to-head comparisons, and long-term metabolic protocols.

Single Certificate of Analysis for Both Peptides

Every batch ships with a unified HPLC chromatogram and mass spectrometry report that verifies the molecular weights of both cagrilintide (~4291 g/mol) and semaglutide (~4113 g/mol) from a single analysis. For this reason, your compliance documentation is streamlined and audit-ready before your compound even arrives.

Clean Comparison Data Across Your Peptide Panel

Many laboratories run the cagrilintide and semaglutide combo alongside our individual cagrilintide, semaglutide, and tirzepatide products. Furthermore, because all peptides are stored and shipped under identical cold-chain conditions, supplier-induced variability is removed from your results.

Domestic Cold-Chain Logistics

Peptide integrity demands temperature control from warehouse to lab bench. Therefore, we use phase-change cooling rated for 96-hour protection, and most orders of the cagrilintide and semaglutide combo reach researchers within 1 to 3 business days.

Synthesis Logs Archived for 24 Months

Should your IRB or compliance office require chain-of-custody records, we provide them without delay.

What Is the Cagrilintide and Semaglutide Combo?

A Dual Amylin/GLP-1 Receptor Agonist Research Blend

The cagrilintide and semaglutide combination is a pre-formulated lyophilized powder containing two long-acting peptide analogs. Cagrilintide is a synthetic 37-amino-acid acylated amylin analog (Novo Nordisk code AM833) with a C16 fatty diacid moiety that extends its half-life to approximately 7 days. Semaglutide is a 31-amino-acid GLP-1 receptor agonist with a similar albumin-binding strategy and a half-life of approximately 7 days. As a result, both peptides are suitable for once-weekly dosing in clinical research models.

Property	Cagrilintide	Semaglutide
Type	Long-acting amylin analog (37 aa)	Long-acting GLP-1 agonist (31 aa)
Receptor	AMY1R, AMY2R, AMY3R + CTR	GLP-1R
Half-life	~7 days	~7 days
Molecular Weight	~4291 g/mol	~4113 g/mol
Acylation	C16 fatty diacid	C18 fatty diacid
Clinical Dose	2.4 mg (CagriSema)	2.4 mg (Wegovy)

Synergy Mechanism: Why the Combination Outperforms Either Peptide Alone

Cagrilintide activates amylin receptors in the brainstem area postrema and dorsal vagal complex, suppressing appetite, slowing gastric emptying, and reducing postprandial glucagon. Semaglutide, on the other hand, activates GLP-1 receptors on pancreatic beta cells and hypothalamic POMC neurons, enhancing insulin secretion and reducing food intake through a distinct neural circuit. Because these two receptor systems operate in parallel rather than in competition, the combined activation produces additive weight loss.

In the REDEFINE-1 trial, the cagrilintide and semaglutide combination produced 22.7% weight loss at 68 weeks, compared to 12.1% for cagrilintide alone and 15.7% for semaglutide alone. This additive pharmacology is precisely what preclinical researchers are now dissecting. Our pre-mixed 5mg/5mg vial gives you the tool to study this synergy at the bench.

Cagrilintide and Semaglutide Dosage: Research Model Reference Chart

The following is compiled from published preclinical and clinical literature. It serves strictly as a laboratory research design context. We do not provide human dosing recommendations.

Research Model	Typical Dose (cagrilintide + semaglutide)	Frequency	Route	Reference
REDEFINE-1 clinical (human, weeks 17+)	2.4 mg + 2.4 mg	Once weekly	SC	NEJM 2025
Rodent DIO (diet-induced obesity)	0.1–0.5 mg/kg each	Every 3–5 days	SC or IP	Novo Nordisk preclinical
Mouse metabolic phenotyping	0.2 mg/kg each	Every 3 days	SC	Published dose-response
Combination head-to-head protocol	Matched doses of combo vs semaglutide alone	Weekly	SC	Institutional protocols
In vitro receptor binding	Nanomolar concentrations	Per assay	—	Cell culture

For researchers searching for a cagrilintide and semaglutide dosing chart, the above table can be printed and posted in the lab. The pre-mixed 5mg/5mg vial is easily reconstituted to cover the typical rodent dose ranges listed.

Cagrilintide vs Semaglutide: Distinct Roles in the Combination

Understanding the individual pharmacology is essential before designing a combination protocol.

Feature	Cagrilintide	Semaglutide
Drug class	Amylin receptor analog	GLP-1 receptor agonist
Primary targets	Brainstem amylin receptors, gastric amylin receptors	Pancreatic beta cells, hypothalamic appetite centers
Physiological effects	Appetite suppression, slowed gastric emptying, glucagon suppression	Insulin secretion, appetite reduction, delayed gastric emptying
Weight loss (Phase 3 mono)	12.1%	15.7%
Weight loss (Phase 3 combo)	22.7% when used as fixed-dose CagriSema
Best research application	Isolating amylin receptor contributions	Studying GLP-1R-mediated effects

The cagrilintide and semaglutide combo is the only way to study these two mechanisms simultaneously without introducing variability from two separate peptide stocks.

How to Reconstitute the Cagrilintide and Semaglutide Combo

Step-by-Step Laboratory Protocol

1. Sanitize the vial stopper with 70% isopropyl alcohol.
2. Inject bacteriostatic water slowly against the vial wall. Avoid aiming directly at the lyophilized cake, because both peptides must dissolve evenly.
3. Allow the powder to dissolve without agitation for 3 to 5 minutes. The hydrophobic C16 and C18 fatty diacid chains on cagrilintide and semaglutide, respectively, mean dissolution may take slightly longer than for unmodified peptides.
4. Gently swirl until the solution is completely clear. Do not shake; foaming can denature both peptides.
5. Verify a clear, colorless solution. Discard if any particulate matter remains.
6. Label with date and concentration.

Concentration Reference for 5mg/5mg Vial (10mg total peptide):

• 5mg/5mg vial + 1 mL bacteriostatic water = 5 mg/mL of each peptide
• 5mg/5mg vial + 2 mL bacteriostatic water = 2.5 mg/mL of each peptide
• 5mg/5mg vial + 5 mL bacteriostatic water = 1 mg/mL of each peptide

Storage Requirements

• Lyophilized powder: 24 months at -20°C, protected from light.
• Reconstituted solution: 28 days at 2 to 8°C. Do not freeze.
• The pre-mixed blend should be handled with the same care as the individual peptides. Avoid repeated freeze-thaw cycles.

Product Specifications

Available Configuration

The cagrilintide and semaglutide research combo is supplied as a 5mg cagrilintide + 5mg semaglutide lyophilized powder vial (10mg total peptide). This fixed ratio provides a flexible starting point for most preclinical protocols.

Quality Verification

• Purity: 98% minimum per peptide (HPLC verified)
• Identity: Mass spectrometry confirmed for both cagrilintide (~4291 g/mol) and semaglutide (~4113 g/mol)
• Endotoxin: Less than 0.1 EU/mL
• Sterility: Verified per USP 71
• Form: Lyophilized powder (pre-mixed blend)
• Storage: -20°C long-term, 2 to 8°C short-term after reconstitution

Current Batch: #PPF-CAGSEMA-5-0526
Purity: 98.7% (cagrilintide), 98.5% (semaglutide)
Download: HPLC Certificate | MS Report

Frequently Asked Questions

What is the cagrilintide and semaglutide combo used for in research?

This pre-mixed blend is used to study additive amylin/GLP-1 receptor pharmacology, obesity models, body composition changes, and comparative protocols against single agents. It mirrors the CagriSema clinical combination at a research scale.

Where can I buy cagrilintide and semaglutide for research?

Pure Peptide Factory stocks the domestic, HPLC-verified combo with same-day cold-chain shipping. Most orders arrive in 1 to 3 business days with full documentation.

What is the cagrilintide and semaglutide dosage for research?

In rodent DIO models, typical doses range from 0.1 to 0.5 mg/kg of each peptide, administered every 3 to 5 days subcutaneously. The pre-mixed 5mg/5mg vial can be reconstituted to cover these ranges. See the dosage chart above for model-specific references.

How does cagrilintide compare to semaglutide?

Cagrilintide is an amylin receptor analog that primarily suppresses appetite and slows gastric emptying. Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion and reduces food intake. By themselves, they produce 12.1% and 15.7% weight loss, respectively; together they act additively. Use the comparison table above to decide which peptide to isolate in your study.

Is this the same as CagriSema?

CagriSema is the clinical fixed-dose combination (2.4 mg cagrilintide + 2.4 mg semaglutide). Our 5mg/5mg research combo contains a different ratio and is intended strictly for laboratory investigation, not as a replica of the clinical formulation.

Can I use this combo to study cagrilintide vs semaglutide?

If your goal is to directly compare the two mechanisms, we recommend using individual cagrilintide and semaglutide peptides. The pre-mixed combo is designed for protocols that require simultaneous activation of both receptors.

How should I store the reconstituted solution?

Keep the solution at 2 to 8°C and use within 28 days. Do not freeze. The lyophilized powder remains stable at -20°C for up to 24 months.

Is the cagrilintide and semaglutide combo FDA approved?

No. The combination is still in clinical trials. Our research-grade peptide is sold exclusively for laboratory use under research-use-only terms.

Can I buy the combo without a prescription?

Yes, for research purposes only. You must agree to our research-use-only terms at checkout.

Order the Cagrilintide and Semaglutide Combo for Research

Secure Checkout

• Credit card, cryptocurrency, or wire transfer
• Same-day dispatch for orders placed before 2 PM EST
• Cold-chain packaging with phase-change cooling
• Discreet labeling with full tracking

Institutional Accounts

Net-30 terms and purchase order acceptance available for universities and research institutions. Contact us for bulk pricing on 50 vials or more, including matched orders alongside our individual amylin, GLP-1, and triple-agonist peptides.

Add to cart and obtain the most thoroughly documented pre-mixed amylin/GLP-1 receptor agonist blend for your metabolic research program.